市場調查報告書

類血友病(VWD)- 流行病學預測 2028年

Von Willebrand Disease (VWD) - Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 524481
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類血友病(VWD)- 流行病學預測 2028年 Von Willebrand Disease (VWD) - Epidemiology Forecast - 2028
出版日期: 2019年11月01日內容資訊: 英文 90 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙)的類血友病(VWD)的總患病數2017年估算為3萬3758人,其數至2028年預計逐漸增加。

本報告提供主要調查7個國家(美國、英國、德國、法國、義大利、西班牙)的類血友病(VWD)調查,疾病概要,整體及各國流行病學的預測,性別、年齡、病型的患病數的變化與預測詳細彙整。

目錄

第1章 重要洞察

第2章 類血友病(VWD):患者概要

  • 患者的分佈情形(實在數值)
  • 患者的分佈情形(預測值)

第3章 疾病背景和概要:類血友病(VWD)

  • 簡介
  • 症狀
  • 分類
  • 原因
  • 臨床症狀
  • 遺傳的根據
  • 病理生理學
  • 診斷
  • 診斷指南
    • 美國國立衛生研究所及國立心肺血液研究所(NHLBI)的VWD診斷、評估、管理
    • 英國血友病中心醫生會的診斷及管理指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的類血友病(VWD)的總患病數

第5章 類血友病(VWD)的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 類血友病(VWD)的患病數
    • 類血友病(VWD)的患病數:性別
    • 類血友病(VWD)的患病數:各病型
    • 類血友病(VWD)的患病數:各年齡
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 附錄

  • 調查方法

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0067

DelveInsight's 'Von Willebrand Disease (VWD)-Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.

Our forecasting model has defined the diagnosed prevalent population of Von Willebrand Disease in children and adults. In the US population, people belonging to the latter half of the first decade and the early first half of the second-decade life (i.e., 0-18 years) reported higher diagnosed prevalence than that of people belonging to other age groups. Whereas, in the German population, people belonging to the age group of 19-44 years reported higher diagnosed prevalence than that of people belonging to other age groups.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Von Willebrand Disease (VWD) - Disease Understanding

Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process.

Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms. Inherited forms are further subdivided into Type 1, 2, and 3 along with a pseudo-VWD. Platelet type disorder which in turn describes their pathophysiology. Type 1 is easily distinguished from type 3 by its milder deficiency and is characterized by a decreased quantity of vWF whereas Type 2 is distinguished on the basis of functional or qualitative deficiencies.

Von Willebrand disease (VWD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Gender-Specific Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Type-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM, and Age-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM) scenario of Von Willebrand disease (VWD) in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017. The number of Von Willebrand disease (VWD) cases in the 7MM is expected to increase during the study period of 2017-2028.

Among the 7MM, the highest diagnosed prevalence of von Willebrand Disease (VWD) is estimated in the United States with 11,336 diagnosed cases in 2017.

DelveInsight's analysts have assessed that approximately 83% of Von Willebrand Disease patients had VWD Type 1, followed by VWD Type 2 (~11%) and Type 3 (~6%). In 2017, there were 9,422 VWD Type 1 patients, 1,250 VWD Type 2 patients, and 664 Type 3 patients in the United States.

Among the European countries, the United Kingdom had the highest diagnosed prevalent population of von Willebrand Disease (VWD) with 10,842 cases, followed by Germany which had diagnosed a prevalent population of 4,040 in 2017. On the other hand, Spain had the lowest diagnosed prevalent population of 740 in 2017.

Japan had 1,285 diagnosed prevalent cases of von Willebrand Disease in 2017.

Von Willebrand disease (VWD) Report Insights

  • The report covers a descriptive overview of the Von Willebrand disease (VWD) Infections, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Von Willebrand disease (VWD) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Von Willebrand disease (VWD) Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation by Total diagnosed cases
  • Gender-specific diagnosed prevalent cases
  • Type-specific diagnosed prevalent cases
  • Age-specific diagnosed prevalent cases

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by Severity

Table of Contents

1. Key Insights

2. Von Willebrand Disease (VWD): Patient Overview at a Glance

  • 2.1. Total Patient Share (%) Distribution of VWD in 2017
  • 2.2. Total Patient Share (%) Distribution of VWD in 2028

3. Disease Background and Overview: Von Willebrand Disease (VWD)

  • 3.1. Introduction
  • 3.2. Symptoms of Von Willebrand disease
  • 3.3. Classification of Von Willebrand disease
  • 3.4. Causes of Von Willebrand disease (VWD)
  • 3.5. Clinical Manifestations of Von Willebrand disease (VWD)
  • 3.6. Genetic Basis of Von Willebrand disease
  • 3.7. Pathophysiology of Von Willebrand disease (VWD)
  • 3.8. Diagnosis of Von Willebrand disease
  • 3.9. Diagnostic Guidelines of Von Willebrand disease (VWD)
    • 3.9.1. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health
    • 3.9.2. The diagnosis of von Willebrand disease: a guideline from the UK Hemophilia Centre Doctor's Organization

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease

5. Country Wise-Epidemiology of von Willebrand Disease

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United States
    • 5.1.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States
    • 5.1.4. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the United States
    • 5.1.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany
      • 5.2.1.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
      • 5.2.1.4. Type-Specific Diagnosed Prevalence of von Willebrand Disease in Germany
      • 5.2.1.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in France
      • 5.2.2.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in France
      • 5.2.2.4. Type Specific Diagnosed Prevalence of Von Willebrand Disease in France
      • 5.2.2.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Italy
      • 5.2.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Italy
      • 5.2.3.4. Type Specific Diagnosed Prevalence of von Willebrand Disease in Italy
      • 5.2.3.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain
      • 5.2.4.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
      • 5.2.4.4. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain
      • 5.2.4.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
      • 5.2.5.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the UK
      • 5.2.5.4. Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the United Kingdom
      • 5.2.5.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
  • 5.3. Japan
    • 5.3.1. Assumptions and rationale
    • 5.3.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Japan
    • 5.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Japan
    • 5.3.4. Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan
    • 5.3.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Japan

6. Appendix

  • 6.1. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Tables

  • Table 1 Classification of von Willebrand disease
  • Table 2 Sub-Classification of von Willebrand disease Type 2A
  • Table 3 Level of Evidence
  • Table 4 Total Diagnosed Prevalent Patient Population of Von Willebrand Disease in the 7MM (2017-2028)
  • Table 5 Total Diagnosed Prevalent Population of Von Willebrand Disease in the United States (2017-2028)
  • Table 6 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Table 7 Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Table 8 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Table 9 Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2017-2028)
  • Table 10 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Table 11 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Table 12 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Table 13 Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2017-2028)
  • Table 14 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Table 15 Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Table 16 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Table 17 Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2017-2028)
  • Table 18 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Table 19 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Table 20 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Table 21 Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2017-2028)
  • Table 22 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Table 23 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Table 24 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Table 25 Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2017-2028)
  • Table 26 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Table 27 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Table 28 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Table 29 Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2017-2028)
  • Table 30 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Table 31 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Table 32 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)

List of Figures

  • Figure 1 The structure of VWF
  • Figure 2 Biosynthesis and Function of von Willebrand Factor
  • Figure 3 Symptoms of Subtypes of Type 2
  • Figure 4 Biosynthesis and Function of von Willebrand Factor
  • Figure 5 Type 2 VWD Variants.
  • Figure 6 Structure and function of pre-pro VWF
  • Figure 7 Pathophysiological Mechanisms and Classification of von Willebrand Disease
  • Figure 8 Initial hemostasis laboratory evaluation
  • Figure 9 Algorithm proposed for the diagnosis and classification of VWD
  • Figure 10 Total Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2017-2028)
  • Figure 11 Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 12 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 13 Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 14 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 15 Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2017-2028)
  • Figure 16 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Figure 17 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Figure 18 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Figure 19 Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2017-2028)
  • Figure 20 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Figure 21 Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Figure 22 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Figure 23 Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2017-2028)
  • Figure 24 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Figure 25 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Figure 26 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Figure 27 Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2017-2028)
  • Figure 28 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Figure 29 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Figure 30 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Figure 31 Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2017-2028)
  • Figure 32 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Figure 33 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Figure 34 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Figure 35 Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2017-2028)
  • Figure 36 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Figure 37 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Figure 38 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
Back to Top